Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Times Arkansas.
Press releases published on May 7, 2025
Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive
GlobeNewswire
·
May 7, 2025
• Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Company to host Corporate Update Call on May 15, 2025 TORONTO, May 07, …
GDS to Report First Quarter 2025 Financial Results Before the Open of the U.S. Market on May 20, 2025
GlobeNewswire
·
May 7, 2025
SHANGHAI, China, May 07, 2025 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced that it will report its …
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
GlobeNewswire
·
May 7, 2025
TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation …
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
GlobeNewswire
·
May 7, 2025
For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues …
Climb Channel Solutions Partners with Smartsheet for Industry-Leading Collaborative Work Management
GlobeNewswire
·
May 7, 2025
EATONTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) is excited to be adding Smartsheet, the AI-enhanced …
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
GlobeNewswire
·
May 7, 2025
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When …
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients
GlobeNewswire
·
May 7, 2025
- Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine …
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
GlobeNewswire
·
May 7, 2025
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 …
Dayforce Reports First Quarter 2025 Results¹
GlobeNewswire
·
May 7, 2025
Dayforce® recurring revenue, excluding float, of $323 million, up 14%, or 16% on a constant currency basis Total revenue of $482 million, up 12%, and excluding float, up 15%, or 17% on a constant currency basis Net cash provided by operating activities of …
Amarin Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing …
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 7, 2025
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease …
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
GlobeNewswire
·
May 7, 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the …
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
GlobeNewswire
·
May 7, 2025
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, analysis showed improvements in both …
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
GlobeNewswire
·
May 7, 2025
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase …
Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
Worldwide revenue of $372.8 million in the first quarter 2025 GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024 …
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
GlobeNewswire
·
May 7, 2025
– Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected …
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product sales SYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by …
Lirum Therapeutics Announces New LX-101 Data in Thyroid Eye Disease Selected for Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
GlobeNewswire
·
May 7, 2025
New York, NY, May 07, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new results with LX-101 in Thyroid Eye Disease …
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
GlobeNewswire
·
May 7, 2025
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases Management will host a conference …
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
May 7, 2025
-- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired …